Diffuse Large B‑ cell Lymphoma – Modern Diagnostics and Molecularly Targeted Treatment

Česká verzia

Authors: R. Pytlík; M. Trněný
Authors place of work: I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze
Published in the journal: Klin Onkol 2015; 28(Supplementum 3): 64-72
doi: https://doi.org/10.14735/amko20153S64

Summary

Background:
Diffuse large B‑ cell lymphoma is a common label for a number of clinico‑ pathological entities, which differ in molecular pathogenesis, clinical presentation and prognosis. Exact correlation between clinico‑ pathological and molecular subtypes of diffuse large B‑ cell lymphoma was not optimally defined; however, key signal transduction pathways were identified; blockage of these pathways may be therapeutically significant.

Aim:
The purpose of this review is to show current approach to diagnostics of diffuse large B‑ cell lymphoma on molecular levels, to summarize current first‑line treatment options for newly diagnosed diffuse large B‑ cell lymphoma patients and to introduce new treatment possibilities, which are currently under investigation in clinical trials.

Results:
Current molecular diagnostics of diffuse large B‑ cell lymphoma is evolving in two main directions. One direction is classification according to gene expression or protein levels. According to these studies, patients may be divided into subgroups according to the cell of origin or according their stromal signature. Most frequently used is classification according cell of origin (COO), which divides diffuse large B-cell lymphomas into GCB subtype (germinal B-cell like) or ABC subtype (activated B-cell like). Second direction is studying genetic information on DNA level, where genetic mutations, deletions, amplifications and losses of heterozygozity are identified, which may be specific for subgroups defined by gene expression analysis, but may go across them. Both these directions aim at identifying signaling pathways important for survival and proliferation of tumor cells and in these, to identify targets for pharmacological blockage. Currently, standard of first-line treatment for all patients is antracycline‑based regimen with rituximab, which improved prognosis in both cell of origin subtypes, even if patients in the ABC subgroup have still inferior outcome. There is a number of new drugs with promising effectivity, which are studied in different phases of clinical trials (lenalidomide, bortezomib, idelalisib, venetoclax), but their possible effectivity will be limited only for precisely defined molecular subtypes of diffuse large B‑ cell lymphoma.

Conclusion:
The advent of new targeted drugs for diffuse large B‑ cell lymphoma is still awaited. For their effective use, besides the proof of their effectivity in randomized studies, also the extension of use of molecular methods in routine diagnostics and ensuring their wide availability will be necessary.

Key words:
diffuse large B‑ cell lymphoma – gene expression profiling – signal transduction pathways – treatment

This study was supported by grants of Internal Grant Agency of the Czech Ministry of Health No. NT13072-4/2012 and NT12193-5/2011.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
25. 9. 2015

Accepted:
28. 9. 2015

Zdroje

1. Winter JN, Variakojis D, Epstein AL. Phenotypic analysis of established diffuse histiocytic lymphoma cell lines utilizing monoclonal antibodies and cytochemical techniques. Blood 1984; 63(1): 140– 146.

2. Shawler DL, Wormsley SB, Dillman RO et al. The use of monoclonal antibodies and flow cytometry to detect peripheral blood and bone marrow involvement of a diffuse, poorly differentiated lymphoma. Int J Immunopharmacol 1985; 7(4): 423– 432.

3. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B‑ cell lymphoma identified by gene expression profiling. Nature 2000; 403(6769): 503– 511.

4. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B‑ cell lymphoma outcome prediction by gene‑ expression profiling and supervised machine learning. Nat Med 2002; 8(1): 68– 74.

5. Monti S, Savage KJ, Kutok JL et al. Molecular profiling of diffuse large B‑ cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105(5): 1851– 1861.

6. Tirado CA, Chen W, García R et al. Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B‑ cell lymphoma: a review of the literature. J Hematol Oncol 2012; 5: 54. doi: 10.1186/ 1756‑ 8722‑ 5‑ 54.

7. Nedomova R, Papajik T, Prochazka V et al. Cytogenetics and molecular cytogenetics in diffuse large B‑ cell lymphoma (DLBCL). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157(3): 239– 247.

8. Jardin F. Next generation sequencing and the management of diffuse large B‑ cell lymphoma: from whole exome analysis to targeted therapy. Discov Med 2014; 18(97): 51– 65.

9. Scott DW, Mottok A, Ennishi D et al. Prognostic significance of diffuse large B‑ cell lymphoma cell of origin determined by digital gene expression in formalin‑fixed paraffin‑embedded tissue biopsies. J Clin Oncol 2015; 33(26): 2848– 2856. doi: 10.1200/ JCO.2014.60.2383.

10. Armitage JO, Corder MP, Leimert JT et al. Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy. Cancer Treat Rep 1980; 64(4– 5): 649– 654.

11. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large‑ B‑ cell lymphoma. N Engl J Med 2002; 346(4): 235– 242.

12. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B‑ cell lymphoma in British Columbia. J Clin Oncol 2005; 23(22): 5027– 5033.

13. Pfreundschuh M, Trümper L, Osterborg A et al. CHOP‑like chemotherapy plus rituximab versus CHOP‑like chemotherapy alone in young patients with good‑ prognosis diffuse large‑ B‑ cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7(5): 379– 391.

14. Niemann CU, Wiestner A. B‑ cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013; 23(6): 410– 421. doi: 10.1016/ j.semcancer.2013.09.001.

15. Majchrzak A, Witkowska M, Smolewski P. Inhibition of the PI3K/ Akt/ mTOR signaling pathway in diffuse large B‑ cell lymphoma: current knowledge and clinical significance. Molecules 2014; 19(9): 14304– 14315. doi: 10.3390/ molecules190914304.

16. Lenz G, Wright G, Dave Ss et al. Stromal gene signatures in large‑ B‑ cell lymphomas. N Engl J Med 2008; 359(22): 2313– 2323. doi: 10.1056/ NEJMoa0802885.

17. Pohlreich D, Vacková B, Pytlík R et al. Záchranná léčba a role transplantací u lymfomů. Klin Onkol 2015; 28 (Suppl 3):3S95–3S104. doi: 10.14735/ amko20153S95.

18. Stein H, Varnke RA, Chan WC et al. Diffuse large B‑ cell lymphoma, not otherwise specified. In: Swerdlow SH et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer 2008: 233– 237.

19. Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198(6): 851– 862.

20. Dave SS, Fu K, Wright GW et al. Molecular diagnosis of Burkitt‘s lymphoma. N Engl J Med 2006; 354(23): 2431– 2442.

21. Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt‘s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354(23): 2419– 2430.

22. Malumbres R, Chen J, Tibshirani R et al. Paraffin‑based 6- gene model predicts outcome in diffuse large B‑ cell lymphoma patients treated with R‑ CHOP. Blood 2008; 111(12): 5509– 5514. doi: 10.1182/ blood‑ 2008‑ 02‑ 136374.

23. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B‑ cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103(1): 275– 282.

24. Coutinho R, Clear AJ, Owen A et al. Poor concordance among nine immunohistochemistry classifiers of cell‑ of‑ origin for diffuse large B‑ cell lymphoma: implications for therapeutic strategies. Clin Cancer Res 2013; 19(24): 6686– 6695. doi: 10.1158/ 1078‑ 0432.CCR‑ 13‑ 1482.

25. Gutiérrez‑ García G, Cardesa‑ Salzmann T, Climent F et al. Gene‑ expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B‑ cell lymphoma treated with immunochemotherapy. Blood 2011; 117(18): 4836– 4843.

26. Benesova K, Forsterova K, Votavova H et al. The Hans algorithm failed to predict outcome in patients with diffuse large B‑ cell lymphoma treated with rituximab. Neoplasma 2013; 60(1): 68– 73. doi: 10.4149/ neo_2013_010.

27. Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr Protoc Mol Biol 2011; chapter 25: unit25B.10. doi: 10.1002/ 0471142727.mb25b10s94.

28. Scott DW, Wright GW, Williams PM et al. Determining cell‑ of‑ origin subtypes of diffuse large B‑ cell lymphoma using gene expression in formalin‑fixed paraffin‑embedded tissue. Blood 2014; 123(8): 1214– 1217. doi: 10.1182/ blood‑ 2013‑ 11‑ 536433.

29. Scott DW, Mottok A, Ennishi D et al. Prognostic significance of diffuse large B‑ cell lymphoma cell of origin determined by digital gene expression in formalin‑fixed paraffin‑embedded tissue biopsies. J Clin Oncol 2015; 33(26): 2848– 2856. doi: 10.1200/ JCO.2014.60.2383.

30. Intlekofer AM, Younes A. Precision therapy for lymphoma – current state and future directions. Nat Rev Clin Oncol 2014; 11(10): 585– 596. doi: 10.1038/ nrclinonc.2014.137.

31. Dunleavy K, Wilson WH. Appropriate management of molecular subtypes of diffuse large B‑ cell lymphoma.

Oncology (Williston Park) 2014; 28(4): 326– 334.

32. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diffuse large B‑ cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30(28): 3452– 3459.

33. A predictive model for aggressive non‑Hodgkin‘s lymphoma. The International Non‑ Hodgkin‘s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329(14): 987– 994.

34. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R‑ IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B‑ cell lymphoma treated with R‑ CHOP. Blood 2007; 109(5): 1857– 1861.

35. Zhou Z, Sehn LH, Rademaker AW et al. An enhanced International Prognostic Index (NCCN‑ IPI) for patients with diffuse large B‑ cell lymphoma treated in the rituximab era. Blood 2014; 123(6): 837– 842. doi: 10.1182/ blood‑2013‑ 09‑ 524108.

36. Hamlin PA, Zelenetz AD, Kewalramani T et al. Age‑ adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B‑ cell lymphoma. Blood 2003; 102(6): 1989– 1996.

37. Advani RH, Chen H, Habermann TM et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‑ cell lymphoma treated with R‑ CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‑ IPI). Br J Haematol 2010; 151(2): 143– 151.

38. Procházka V, Pytlík R, Janíková A et al. A new prognostic score for elderly patients with diffuse large B‑ cell lymphoma treated with R‑ CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. PLoS One 2014; 9(7): e102594. doi: 10.1371/ journal.pone.0102594.

39. Pfreundschuh M, Trümper L, Kloess M et al. Two‑weekly or 3‑weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good‑ prognosis (normal LDH) aggressive lymphomas: results of the NHL‑B1 trial of the DSHNHL. Blood 2004; 104(3): 626– 633.

40. Pfreundschuh M, Trümper L, Kloess M et al.Two‑weekly or 3‑weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL‑B2 trial of the DSHNHL. Blood 2004; 104(3): 634– 641.

41. Cunningham D, Hawkes EA, Jack A et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B‑ cell non‑Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14- day versus 21- day cycles. Lancet 2013; 381(9880): 1817– 1826. doi: 10.1016/ S0140‑ 6736(13)60313‑ X.

42. Delarue R, Tilly H, Mounier N et al. Dose‑dense rituximab‑ CHOP compared with standard rituximab‑ CHOP in elderly patients with diffuse large B‑ cell lymphoma (the LNH03- 6B study): a randomised phase 3 trial. Lancet Oncol 2013; 14(6): 525– 533. doi: 10.1016/ S1470‑ 2045(13)70122‑ 0.

43. Pfreundschuh M, Nickening C, Kannourakis G et al. Rituximab as a „chemo‑ equalizer“ in the MInT (Mabthera International Trial Group) study: treatment results of CHOP‑ 21, CHOEP‑ 21, MACOP‑ B and PMitCEBO with and without rituximab in young good‑ prognosis patients with aggressive lymphomas. Ann Oncol 2005; 16 (Suppl 5): v98.

44. Vitolo U, Chiapella A, Brusamolino E et al. Randomized multicentre phase III study for first line treatment of young patients with high risk (aaIPI 2– 3) diffuse large B‑ cell lymphoma (DLBCL): Rituximab (R) plus dose‑dense chemotherapy CHOP14/ MegaCHOP14 with or without intensified high‑dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial of Italian Lymphoma Foundation (FIL) [abstract]. Ann Oncol 2011; 22 (Suppl 4): iv106.

45. Schmitz N, Nickelsen M, Ziepert M et al. Conventional chemotherapy (CHOEP‑ 14) with rituximab or high‑dose chemotherapy (MegaCHOEP) with rituximab for young, high‑risk patients with aggressive B‑ cell lymphoma: an open‑ label, randomised, phase 3 trial (DSHNHL 2002- 1). Lancet Oncol 2012; 13(12): 1250– 1259. doi: 10.1016/ S1470‑ 2045(12)70481‑ 3.

46. Cortelazzo S, Tarella C, Gianni AM et al. Chemoimmunotherapy with R‑ CHOP or high dose sequential therapy (R‑ HDS) with autologous stem cell transplantation (ASCT) for high risk DLBCL patients: preliminary results of the randomized RHDS0305 trial by Gruppo Italiano Terapie Inovative nei Linfomi (GITIL) [abstract]. Hematol Oncol 2013; 31 (Suppl 1): 136.

47. Stiff PJ, Unger JM, Cook R et al. Autologous transplantation as consolidation for aggressive non‑Hodgkin‘s lymphoma. N Engl J Med 2013; 369(18): 1681– 1690. doi: 10.1056/ NEJMoa1301077.

48. Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non‑Hodgkin’s lymphoma. J Clin Oncol 2008; 26(30): 4952– 4957. doi: 10.1200/ JCO.2007.15.3429.

49. Witzig TE, Vose JM, Zinzani PL et al. An international phase II trial of single‑agent lenalidomide for relapsed or refractory aggressive B‑ cell non‑Hodgkin’s lymphoma. Ann Oncol 2011; 22(7): 1622– 1627. doi: 10.1093/ annonc/ mdq626.

50. Lopez‑ Girona A, Mendy D, Ito T et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26(11): 2326– 2335. doi: 10.1038/ leu.2012.119.

51. Zhang LH, Kosek J, Wang M et al. Lenalidomide efficacy in activated B‑ cell‑like subtype diffuse large B‑ cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013; 160(4): 487– 502. doi: 10.1111/ bjh.12172.

52. Hernandez‑ Ilizaliturri FJ, Deeb G, Zinzani PL et al. Higher response to lenalidomide in relapsed/ refractory diffuse large B‑ cell lymphoma in nongerminal center B‑ cell‑like than in germinal center B‑ cell‑like phenotype. Cancer 2011; 117(22): 5058– 5066. doi: 10.1002/ cncr.26135.

53. Nowakowski GS, LaPlant B, Macon WR et al. Lenalidomide combined with R‑ CHOP overcomes negative prognostic impact of non‑germinal center B‑ cell phenotype in newly diagnosed diffuse large B‑ Cell lymphoma: a phase II study. J Clin Oncol 2015; 33(3): 251– 257. doi: 10.1200/ JCO.2014.55.5714.

54. Karin M, Yamamoto Y, Wang QM. The IKK NF‑ kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3(1): 17– 26.

55. Qin JZ, Ziffra J, Stennett L et al. Proteasome inhibitors trigger NOXA‑ mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65(14): 6282– 6293.

56. Landowski TH, Megli CJ, Nullmeyer KD et al. Mitochondrial‑ mediated disregulation of Ca2+ is a critical determinant of Velcade (PS‑ 341/ bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005; 65(9): 3828– 3836.

57. Befani CD, Vlachostergios PJ, Hatzidaki E et al. Bortezomib represses HIF‑ 1α protein expression and nuclear accumulation by inhibiting both PI3K/ Akt/ TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl) 2012; 90(1): 45– 54. doi: 10.1007/ s00109‑ 011‑ 0805‑ 8.

58. Pellom ST Jr, Dudimah DF, Thounaojam MC et al. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. In press 2015.

59. Dunleavy K, Pittaluga S, Czuczman MS et al. Differential efficacy of bortezomib plus chemotherapy

within molecular subtypes of diffuse large B‑ cell lymphoma. Blood 2009; 113(24): 6069– 6676. doi: 10.1182/ blood‑ 2009‑ 01‑ 199679.

60. Ruan J, Martin P, Furman Rr et al. Bortezomib plus CHOP‑ rituximab for previously untreated diffuse large B‑ cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29(6): 690– 697. doi: 10.1200/ JCO.2010.31.1142.

61. Vajpayee N, Thakral C, Gopaluni S et al. Activation of mammalian target of rapamycin in diffuse large B‑ cell lymphoma: a clinicopathological study. Leuk Res 2012; 36(11): 1403– 1409. doi: 10.1016/ j.leukres.2012.07.016.

62. Balasubramanian S, Crowley R, Sirisawad M et al. The Bruton‘s tyrosine kinase (BTK) inhibitor PCI‑ 32765 inhibits growth of ABC DLBCL tumors in vivo and in vitro by preventing activation of pro‑survival NF‑ κB pathways. Blood 2011; 118: abstr. 4969.

63. Wilson WH, Gerecitano JF, Goy A et al. The Bruton’s Tyrosine kinase (BTK) inhibitor, ibrutinib (PCI‑ 32765), has preferential activity in the ABC subtype of relapsed/ refractory de novo diffuse large B‑ cell lymphoma (DLBCL): interim results of a multicenter, open‑ label, phase 2 study. Blood 2012; 120: 686.

64. Younes A, Thieblemont C, Morschhauser F et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‑ CHOP) for treatment‑ naive patients with CD20- positive B‑ cell non‑Hodgkin lymphoma: a non‑randomised, phase 1b study. Lancet Oncol 2014; 15(9): 1019– 1126. doi: 10.1016/ S1470‑ 2045(14)70311‑ 0.

65. Dasmahapatra G, Patel H, Dent P et al. The Bruton tyrosine kinase (BTK) inhibitor PCI‑ 32765 synergistically increases proteasome inhibitor activity in diffuse large‑ B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013; 161(1): 43– 56. doi: 10.1111/ bjh.12206.

66. Dunleavy K, Wilson WH. Differential role of BCL2 in molecular subtypes of diffuse large B‑ cell lymphoma. Clin Cancer Res 2011; 17(24): 7505– 7507. doi: 10.1158/ 1078‑ 0432.CCR‑ 11‑ 2372.

67. Zivny J, Klener P Jr, Pytlik R et al. The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Curr Pharm Des 2010; 16(1): 11– 33.

68. Green TM, Young KH, Visco C et al. Immuno-histochemical double‑hit score is a strong predictor of outcome in patients with diffuse large B‑ cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30(28): 3460– 3467.

69. Hu S, Xu‑ Monette ZY, Tzankov A et al. MYC/ BCL2 protein coexpression contributes to the inferior survival of activated B‑ cell subtype of diffuse large B‑ cell lymphoma and demonstrates high‑risk gene expression signatures: a report from the International DLBCL Rituximab‑ CHOP Consortium Program. Blood 2013; 121(20): 4021– 4031. doi: 10.1182/ blood‑ 2012‑ 10‑ 460063.

70. Pro B, Leber B, Smith M et al. Phase II multicenter study of oblimersen sodium, a Bcl‑ 2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‑ cell non‑Hodgkin lymphoma. Br J Haematol 2008; 143(3): 355– 360. doi: 10.1111/ j.1365‑ 2141.2008.07353.x.

71. O‘Brien S, Moore JO, Boyd TE et al. 5‑year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27(31): 5208– 5212. doi: 10.1200/ JCO.2009.22.5748.

72. Kipps TJ, Eradat H, Grosicki S et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT‑ 263) with or without rituximab, in previously untreated B‑ cell chronic lymphocytic leukemia. Leuk Lymphoma. In press 2015.

73. Johnson‑ Farley N, Veliz J, Bhagavathi S et al. ABT‑ 199, a BH3 mimetic that specifically targets Bcl‑ 2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in „double hit“ lymphoma cells. Leuk Lymphoma 2015; 56(7): 2146– 2152. doi: 10.3109/ 10428194.2014.981172.

74. de Vos S, Flowers CR, Wang D et al. The BCL‑ 2 inhibitor ABT‑ 199 (GDC‑ 0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non‑Hodgin’s lymphoma. Blood 2014; 124(21): abstr. 1722.